Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix

Launched by TATA MEMORIAL HOSPITAL · Sep 13, 2005

Keywords

ClinConnect Summary

Carcinoma cervix is the commonest malignancy seen in Asian women and constitutes approximately 30% of all cancers (1). It is also the leading cause of cancer mortality in India. Nearly 50% of the patients present with advanced stages (FIGO Stage III/IV). The main stay of treatment has traditionally been radical radiation therapy and over decades the survival rates have achieved a plateau of 30 - 45% at 5 years. In developing countries the socioeconomic problems, illiteracy, late presentation and irregular follow-up have further compromised our survivals. Over the last decade there have been...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven squamous carcinoma of cervix
• • Performance index world health organization (WHO) grade 0 or 1
• • Patients below 65 years of age
• • FIGO Stage IIIB
• • Normal ECG and Cardiovascular system
• • Normal hematological parameters
• • Normal renal and liver function tests
• Exclusion Criteria:
• • Co-morbid conditions like medical renal disease
• • Medical or Psychological condition that would preclude treatment
• • H/o Previous treatment / Pregnancy
• • Patient unreliable for treatment completion and follow-up.